Mucosis Receives Financial Support from the Dutch Government for its SynGEM® Program

(PresseBox) ( Groningen, the Netherlands, )
Biotechnology company Mucosis B.V. today announced that it has received an innovation credit line of up to €5 million from the Netherlands Enterprise Agency, an agency of the Dutch Ministry of Economic Affairs.

Mucosis will use these funds to further advance the clinical development of its proprietary SynGEM® prefusion F RSV vaccine candidate through human proof-of-concept studies. These studies aim to demonstrate both safety and protection against a challenge with RSV in healthy volunteers.

"We are delighted to have the support of the Dutch government in such an important disease area. Combined with our recently announced strategic partnership with BCHT of China and new investment round, we have now raised over €10 million in the first half of 2014. Advancing the SynGEM® program to human clinical trials through these funds will create a substantial company value inflection point in the near term", said Thomas Johnston, CEO of Mucosis. "Additionally, we see this significant funding as a further validation of our clinical-stage Mimopath® platform and its potential to combat the most challenging of infectious diseases."

About Mimopath® technology

The Mimopath® technology is based on Lactococcus lactis, a Generally Recognized As Safe (GRAS) bacterium commonly used in the food industry. Mucosis has developed a robust proprietary technique to formulate the L. lactis bacteria into non-living bacterium-like particles (BLPs) that can be covered with antigens from viral, bacterial, parasitic or tumor origin. BLP-based vaccines are particularly suitable to administer into the nose or mouth, without the need for a needle. Such mucosal vaccines have been shown to raise protective immunity by activation of both the innate and the adaptive immune system.

About SynGEM®

SynGEM®, Mucosis's lead vaccine candidate that is currently completing preclinical studies, is being developed in cooperation with corporate, governmental and non-governmental partners across the globe. SynGEM® is designed to prevent infections with Respiratory Syncytial Virus (RSV), which affect over 60 million people worldwide ranging from the very young to the elderly with more than one million hospitalizations and 160,000 deaths annually. The unique stabilized RSV prefusion F protein in SynGEM® displays the epitopes thought to be most important for optimal virus neutralization and is suitable for use in different formulations and administration routes to efficiently address various target groups. An RSV vaccine does not yet exist.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an